PUMVC3 DNA vaccine (IGFBP2/HER2/IGF1R)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePUMVC3 DNA vaccine (IGFBP2/HER2/IGF1R)
Drug Alias NameWOKVACpUMVC3-IG FBP2-HER2-IGF1R
ClassificationVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsLymphadenopathyNeoplasm, ResidualBreast Neoplasms, Male +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of WashingtonUniversity Of Wisconsin-MadisonNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesH Lee Moffitt Cancer Center & Research InstituteNational Cancer InstituteUniversity Of Wisconsin-Madison +[4] 
Inactive CompaniesN/A
Active IndicationsLymphadenopathyNeoplasm, ResidualBreast Neoplasms, Male +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A